AERI - Aerie Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
23.62
-0.40 (-1.67%)
At close: 4:00PM EDT

23.62 0.00 (0.00%)
After hours: 4:53PM EDT

Stock chart is not supported by your current browser
Previous close24.02
Open23.95
Bid23.55 x 1200
Ask26.00 x 800
Day's range23.21 - 23.95
52-week range23.12 - 74.75
Volume545,841
Avg. volume647,037
Market cap1.085B
Beta (3Y monthly)0.53
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
All
News
Press releases
  • Business Wire10 days ago

    Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that enrollment for its Phase 2 clinical trial of netarsudil ophthalmic solution in Japan is complete, a milestone reached several months earlier than previously anticipated. In approximately 3 months, a total of 215 patients were successfully randomized across four treatment arms: netarsudil ophthalmic solution 0.01%, netarsudil ophthalmic solution 0.02%, netarsudil ophthalmic solution 0.04%, and placebo, all administered once daily in the evening. Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa® in the United States where it is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • Business Wirelast month

    Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Jeffrey Calabrese, CPA, as Director of Accounting, reporting to Christopher Staten, Aerie’s Vice President of Finance. Mr. Calabrese will lead external financial reporting, technical accounting and equity accounting. In connection with his acceptance of the position as Director of Accounting, Mr. Calabrese will receive awards totaling 14,400 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date.

  • Business Wirelast month

    Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

    Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the trea

  • Business Wire2 months ago

    Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 2:30 p.m. Eastern Time in New York, NY. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

  • Business Wire2 months ago

    Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

    Conference Call and Webcast Today, May 7th, at 5:00 p.m. ET

  • Business Wire3 months ago

    Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it has entered into an amendment of its existing credit agreement with certain affiliates of Deerfield Management Company L.P. (Deerfield). The amendment provides for an additional $100 million senior secured delayed draw term loan facility (the additional credit facility), pursuant to which Aerie may borrow up to $100 million in aggregate in one or more borrowings at any time on or prior to July 23, 2020. Amounts drawn under the additional credit facility will amortize in equal annual installments beginning on July 20, 2023 and will mature on July 23, 2024.

  • Business Wire3 months ago

    Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it has launched Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% into the United States glaucoma market. Rocklatan® is now with national and regional U.S. pharmaceutical wholesalers, and patients can fill prescriptions for Rocklatan® through their local pharmacies across the nation. Additionally, effective May 1, Medicare Part D preferred tier coverage for Rhopressa® (netarsudil ophthalmic solution) 0.02% increased from approximately 40% to 75%.

  • Business Wire3 months ago

    Aerie Pharmaceuticals to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its first quarter 2019 financial results will be released after the market closes on Tuesday, May 7, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com.

  • Business Wire3 months ago

    Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has reviewed the Investigational New Drug Application (IND) for AR-13503, a novel multi-kinase (Rho kinase/Protein kinase C (ROCK/PKC)) inhibitor sustained-release implant (the AR-13503 implant) and it is now in effect, allowing Aerie to initiate human studies in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The IND was submitted in March 2019.

  • Business Wire4 months ago

    Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 1:30 p.m. Eastern Time in New York, NY. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

  • Business Wire4 months ago

    Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe, reporting to Thomas Mitro, Aerie’s President and Chief Operating Officer. Mr. Corbinelli will be responsible for overseeing the execution of all aspects of Aerie’s commercialization activities in Europe, to develop the commercial infrastructure necessary to support Aerie’s business plans in Europe including ultimately the successful commercialization of products in the region upon their approval.

  • Business Wire4 months ago

    Aerie Pharmaceuticals Announces Four Appointments

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of David Ellis, Ph.D., as Director, Chemistry, reporting to Mitchell deLong, Ph.D., Aerie’s Vice President of Chemistry. Dr. Ellis will be responsible for advancing the Company’s creation and optimization of new chemical entities to support the growth and advancement of Aerie’s pipeline. Dr. Ellis most recently held a related position at Novartis.

  • Business Wire4 months ago

    Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa® in the United States and is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • Business Wire4 months ago

    Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This Phase 2 study (AR1105-CS201) will be conducted at approximately 20 centers in the United States and enroll up to 45 patients. In the initial safety stage, up to 5 patients will be enrolled in a single cohort to receive clinical formulation #1 (CF-1), delivering a 340µg dose of dexamethasone in a single intravitreal injection.

  • Business Wire4 months ago

    Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced full-year 2019 net revenue and net cash burn guidance. With the recently announced FDA approval of RocklatanTM (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the Company announced full-year 2019 net revenue guidance in the range of $110 million to $120 million. This guidance includes the combined net revenues for Rhopressa® (netarsudil ophthalmic solution) 0.02% and RocklatanTM.

  • Business Wire4 months ago

    Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. A link to the full product label is available on the Aerie website at http://investors.aeriepharma.com.

  • Business Wire4 months ago

    Aerie Pharmaceuticals to Present at Two Investor Conferences in March

    Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present an Aerie overview and provide a business update ...

  • Business Wire5 months ago

    Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update

    Conference Call and Webcast Today, February 25th, at 5:00 p.m. ET

  • Business Wire5 months ago

    Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its fourth quarter and full year 2018 financial results will be released after the market closes on Monday, February 25, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results, provide 2019 cash burn guidance and a general business update. The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com.

  • Business Wire6 months ago

    Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant)

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye today announced that the U.S. Food and Drug Administration (FDA) has reviewed the Investigational New Drug Application (IND) for AR-1105 (dexamethasone intravitreal implant) and it is now in effect, allowing Aerie to initiate human studies in the treatment of macular edema due to retinal vein occlusion (RVO). The IND was submitted in December 2018.

  • Business Wire6 months ago

    Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye today announced the topline results of its pilot Phase 2 study of netarsudil ophthalmic solution in a Japanese-American population. The study was designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support the potential regulatory submission of netarsudil ophthalmic solution in Japan.

  • Business Wire7 months ago

    Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Ami Bavishi as Director, Investor Relations, reporting to Richard Rubino, Aerie’s Chief Financial Officer. Ms. Bavishi will drive all of Aerie’s investor relations activities, and joins Aerie from Burns McClellan, a public relations and investor relations firm with which Aerie will maintain an ongoing relationship.

  • Business Wire8 months ago

    Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 at 10:15 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.

  • Business Wire8 months ago

    Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    Conference Call and Webcast Today, November 6th, at 5:00 p.m. ET

  • Business Wire9 months ago

    Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie or the Company), announced today that its third quarter 2018 financial results will be released after the market closes on Tuesday, November 6, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company's website at http://investors.aeriepharma.com.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes